Description
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the structure of erythropoietin (EPO). It is engineered to selectively bind to the innate repair receptor (IRR) to trigger tissue-protective, anti-inflammatory, and neuroprotective pathways. Unlike full-length EPO, ARA-290 isolates these healing properties without stimulating red blood cell production, successfully avoiding associated cardiovascular and thrombotic risks.
Currently, ARA-290 is classified strictly as an investigational compound that is not for human use. It has not received FDA approval or standard commercial clearance, meaning any online availability from research chemical vendors falls entirely outside regulatory safety frameworks. There is no legal pathway for its clinical prescription or public use.
Data from completed Phase II clinical trials highlight its experimental effects:
-
- Sarcoidosis-Associated Small-Fiber Neuropathy: In a Phase IIb randomized controlled trial, a 4 mg daily subcutaneous dose for 28 days demonstrated a statistically significant increase in corneal nerve fiber density. However, the study did not establish lasting functional nerve recovery, and subjective pain reduction endpoints did not cleanly separate from the placebo group.
- Type 2 Diabetes: A separate Phase II study exploring diabetic painful neuropathy noted significant improvements in neuropathic symptoms alongside secondary metabolic markers, such as HbA1c and lipid profiles, over a 56-day observation window.
Despite these proof-of-concept findings, Phase III trials were never initiated, and formal drug development stalled following the closure of its originating developer, Araim Pharmaceuticals.
The vials we provide contain 10mg of ARA-290 and are for research use only.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.